Management of patients with Alzheimer’s disease: pharmacological treatment and quality of life
Authors:
Open Access
- 2 July 2012
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Chronic Disease
- Vol. 3 (4) , 183-193
Abstract
A methodological approach to quality of life (QoL) assessment in Alzheimer’s disease (AD) is challenging and few clinical trials have included it among outcomes, with conflicting results. In this review an indirect appraisal of evidence has been performed, searching the literature for the effect of drug treatments on determinants of QoL in AD. Among clinical factors associated with QoL, possible targets of drugs include cognition, which seems to be associated with QoL in early disease and can be positively affected by cholinesterase inhibitors (CIs) in this stage; functional decline, the risk of which can be decreased by CIs and memantine (MEM); behavioral and psychological symptoms, which can be reduced by MEM and atypical antipsychotics. Long-term observational studies have associated CIs and MEM treatment with a reduced institutionalization risk. According to the evidence, drug treatment of depression associated with AD should not be first choice from a QoL perspective, while treatment of pain can have beneficial effects on wellbeing indicators also in the late stages of the disease. Possible drug-related adverse events can affect QoL and should always be weighed against expected benefits from the patient’s perspective. For this reason antipsychotic treatment is often problematic in AD and should be limited to severe psychosis and aggression, using the lowest effective doses for the shortest possible period. Conversely titration of CIs is necessary to reach the most effective dosages, although dose-related risk of adverse events has to be taken into account. Finally, CIs and MEM have been shown to reduce caregiver burden in randomized trials, possibly affecting caregivers’ QoL.Keywords
This publication has 76 references indexed in Scilit:
- Factors Associated with Self and Informant Ratings of the Quality of Life of People with Dementia Living in Care Facilities: A Cross Sectional StudyPLOS ONE, 2010
- Quality of Life in Nursing Home Residents with Advanced DementiaJournal of the American Geriatrics Society, 2010
- Risk Factors for Nursing Home Placement in Alzheimer's Disease: A Longitudinal Study of Cognition, ADL, Service Utilization, and Cholinesterase Inhibitor TreatmentThe Gerontologist, 2010
- Effectiveness of Donepezil in Reducing Clinical Worsening in Patients with Mild-to-Moderate Alzheimer’s DiseaseDementia and Geriatric Cognitive Disorders, 2009
- Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer diseaseJournal of Neurology, Neurosurgery & Psychiatry, 2009
- Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer’s Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness TrialAmerican Journal of Psychiatry, 2008
- Functional Outcomes of Drug Treatment in Alzheimer???s DiseaseDrugs & Aging, 2007
- Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's DiseaseNew England Journal of Medicine, 2006
- Effect of Acetaminophen on Behavior, Well‐Being, and Psychotropic Medication Use in Nursing Home Residents with Moderate‐to‐Severe DementiaJournal of the American Geriatrics Society, 2005
- Resource Utilisation and Cost Analysis of Memantine in Patients with Moderate to Severe Alzheimer??s DiseasePharmacoEconomics, 2003